乳腺癌新辅助化疗疗效与疾病预后研究进展  

The study progress on the effect of neoadjuvant chemotherapy for breast cancer and its prognosis

作　　者：于辰华 陆苏[1] 刘红[1] YU Chenhua;LU Su;LIU Hong(The Second Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer; Tianjin Key Laboratory of Cancer Prevention and Therapy; Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University, Ministry of)

机构地区：[1]天津医科大学肿瘤医院乳腺二科,国家肿瘤临床医学研究中心,天津市肿瘤防治重点实验室,乳腺癌防治教育部重点实验室,300060

出　　处：《天津医药》2016年第12期1518-1520,共3页Tianjin Medical Journal

摘　　要：新辅助化疗用于乳腺癌已有多年,并已取得可喜成绩,但其远期疗效及对疾病预后的影响尚不明确。据目前资料显示,乳腺癌新辅助化疗后,乳腺及腋窝淋巴结均无浸润性癌及原位癌成分的病理完全缓解的患者有着较好的远期获益,而对于侵袭性较强分子分型的乳腺癌,即使达病理完全缓解的患者仍有相对较高的转移复发风险。目前,尚少见新辅助化疗后残余病灶继续治疗的大型临床试验报道,故该方面的研究成为今后关注的课题。本文对新辅助化疗后病理完全缓解或尚有残余病灶继续治疗的相关研究进行综述,为临床深入开展该疗法提供参考。It has been a long time that neoadjuvant chemotherapy is applied to breast cancer, but the effects on it sprognosis are unclear. According to the current data, it is suggested that the neoadjuvant chemotherapy for breast cancer has long-term benefits in patients without infiltrating carcinoma in lymph nodes and axillary, and without pathological invasive cancer and carcinoma in situ. For patients with more aggressive breast cancer subtypes, even the outcome is pathological complete remission, they still have the high risk of recurrence and metastasis. Currently, there is no data to focus on the several clinical trials about the continue therapy in situ residuals in breast cancer. We expand on the ongoing research focusing on in situ residuals in breast cancer, which will provide reference for further clinical development of this therapy.

关 键 词：乳腺肿瘤 新辅助化疗 病理完全缓解 残余病灶 综述 

分 类 号：R737.9[医药卫生—肿瘤]